The CheckMate 9DW trial (NCT04039607), a phase III clinical trial, evaluated nivolumab (anti–PD-1) in combination with ipilimumab (anti–CTLA-4) in patients with advanced, unresectable HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.